Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Elephas logo — Live tumor profiling for immunotherapy response prediction

Elephas

Live tumor profiling for immunotherapy response prediction

Founded 2020 United States Madison, United States 145 employees Series C Total: $178.50M AI, Biotechnology +1

General Information

Company Name Elephas
Founded Year 2020
Location United States Madison, United States
Employees 145
Industries AI, Biotechnology, Health Care
Funding Stage Series C
Business Model B2B, SaaS, DaaS
Revenue Model Service Fee, Usage Based, Data Monetization
Social

BounceWatch is an independent company data service, not affiliated with Elephas. To contact Elephas, visit elephas.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Elephas compare?

A PDF of Elephas and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Elephas soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Elephas

Elephas, founded in 2020 and headquartered in the United States, is making significant strides in the intersection of AI, Biotechnology, and Health Care. The company's slogan, "Live tumor profiling for immunotherapy response prediction," highlights its core innovation: an ex-vivo platform that analyzes live patient biopsies for immunotherapy response.

The Elephas Live platform distinguishes itself by preserving the tumor's native microenvironment, allowing for real-time characterizations of immune responses. This approach provides a novel solution to the challenge of tumor heterogeneity, positioning the company as a promising player in personalized cancer treatment.

Recently, Elephas secured a substantial $55.00M Series C investment on 24 January 2024, with notable backers including Sands Capital Ventures, Moore Strategic Ventures, Northpond Ventures, and others. This funding round underscores investor confidence in Elephas's potential to revolutionize cancer care through innovative technology.

Business keywords: ex-vivo platform, tumor profiling, immunotherapy response prediction, live patient biopsies, tumor microenvironment, tumor heterogeneity, real-time immune characterization, oncology diagnostics, patient-centric solutions, cancer biology, multimodal microscopy, clinical decision-making, drug development, oncology innovation

Services & Products

Elephas Live Platform
Immunotherapy Response Prediction
Functional Testing of Live Tissue
Data Aggregation and Analysis

Target Customers

Pathology Labs Healthcare Providers Cancer Researchers Biotechnology Companies

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $55.00M 7
Sands Capital Ventures Moore Strategic Ventures Northpond Ventures
Sands Capital Ventures, Moore Strategic Ventures +5
24 Jan 2024
Series C $55.00M 8
Arch Venture Partners Tao Capital Partners Sands Capital Ventures
Arch Venture Partners, Tao Capital Partners +6
30 Nov 2023
Series B $41.50M 6
Arch Venture Partners Tao Capital Partners Sands Capital Ventures
Arch Venture Partners, Tao Capital Partners +4
06 Sep 2022
Series A $20.00M 3
Sands Capital Ventures Northpond Ventures
Sands Capital Ventures, Northpond Ventures +1
15 Sep 2021
Seed Round $1.00M -
15 May 2021
Seed Round $6.00M -
13 May 2021

Elephas Alternatives & Competitors

View All Alternatives
Elephas vs
VitroScan
VitroScan The Netherlands

Predictive Testing Solutions

Grant
10 employees
Biopharma, Biotechnology
Compare Elephas vs VitroScan
Elephas vs
Farcast Biosciences
Farcast Biosciences India

24,000 human tumors and counting - building the most precise functional precision tumor microdynamic...

Pre-Seed
38 employees
Biotechnology, Health Care
Compare Elephas vs Farcast Biosciences
Elephas vs
Sensei Bio
Sensei Bio United States

We follow the immune system’s teachings to discover new treatments that inspire the body to fight ca...

Series B
32 employees
Biotechnology, Health Care
View all alternatives

FAQ About Elephas

Live tumor profiling for immunotherapy response prediction
Elephas was founded in 2020.
Elephas is headquartered in Madison, United States.
Elephas operates in AI, Biotechnology and Health Care. Its work centres on ex-vivo platform, tumor profiling, immunotherapy response prediction and live patient biopsies. Its customers include Pathology Labs, Healthcare Providers and Cancer Researchers.
Elephas has a B2B, SaaS and DaaS business model. Its revenue comes from Service Fee, Usage Based and Data Monetization.
Elephas has approximately 145 employees.
Elephas has completed 6 funding rounds, raising a total of $178.50M. The latest funding stage is Series C.
Elephas offers: Elephas Live Platform, Immunotherapy Response Prediction, Functional Testing of Live Tissue, Data Aggregation and Analysis.
Top alternatives and competitors to Elephas include VitroScan, Farcast Biosciences, Sensei Bio, ImmunoGenesis, Inc., OncoResponse. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Elephas and VitroScan are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Elephas, https://bouncewatch.com/company/elephas, updated 17 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout